BG61474B1 - Method for conditioning of water soluble substances - Google Patents
Method for conditioning of water soluble substances Download PDFInfo
- Publication number
- BG61474B1 BG61474B1 BG98147A BG9814793A BG61474B1 BG 61474 B1 BG61474 B1 BG 61474B1 BG 98147 A BG98147 A BG 98147A BG 9814793 A BG9814793 A BG 9814793A BG 61474 B1 BG61474 B1 BG 61474B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- substances
- conditioning
- solvent
- substance
- inert gas
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 230000003750 conditioning effect Effects 0.000 title claims description 12
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000011261 inert gas Substances 0.000 claims abstract description 7
- 239000013557 residual solvent Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims description 5
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 229960005105 terbutaline sulfate Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000010926 purge Methods 0.000 claims description 3
- 239000012808 vapor phase Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001022 fenoterol Drugs 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims 2
- 230000001088 anti-asthma Effects 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 abstract description 9
- 238000007664 blowing Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- -1 ethanol saturated nitrogen gas Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- HWAXMFYECKQLDX-UHFFFAOYSA-N 5-[[(4-chlorobenzoyl)amino]methyl]thiophene-2-sulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1C(=O)NCC1=CC=C(S(Cl)(=O)=O)S1 HWAXMFYECKQLDX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003416 bambuterol hydrochloride Drugs 0.000 description 1
- 230000000572 bronchospasmolytic effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960004674 theophylline anhydrous Drugs 0.000 description 1
- 238000004861 thermometry Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Treating Waste Gases (AREA)
- Paper (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Hydrogenated Pyridines (AREA)
- General Preparation And Processing Of Foods (AREA)
- Cephalosporin Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9101090A SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Process for conditioning of water-soluble substances |
| PCT/SE1992/000186 WO1992018110A1 (en) | 1991-04-11 | 1992-03-24 | Process for conditioning of water-soluble substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG98147A BG98147A (bg) | 1994-12-02 |
| BG61474B1 true BG61474B1 (en) | 1997-09-30 |
Family
ID=20382434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG98147A BG61474B1 (en) | 1991-04-11 | 1993-10-08 | Method for conditioning of water soluble substances |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5562923A (no) |
| EP (3) | EP0680752B1 (no) |
| JP (2) | JP3400999B2 (no) |
| KR (1) | KR100216384B1 (no) |
| AT (2) | ATE208613T1 (no) |
| AU (1) | AU662519B2 (no) |
| BG (1) | BG61474B1 (no) |
| CA (1) | CA2106975C (no) |
| CZ (1) | CZ286936B6 (no) |
| DE (2) | DE69232207T2 (no) |
| DK (2) | DK0680752T3 (no) |
| EE (1) | EE02970B1 (no) |
| ES (2) | ES2086733T3 (no) |
| FI (1) | FI105388B (no) |
| GR (1) | GR3020602T3 (no) |
| HK (1) | HK52497A (no) |
| HU (1) | HU211116B (no) |
| IE (1) | IE921144A1 (no) |
| IS (1) | IS3834A (no) |
| NO (1) | NO311867B1 (no) |
| PL (1) | PL168232B1 (no) |
| PT (1) | PT680752E (no) |
| RO (1) | RO115779B1 (no) |
| RU (1) | RU2112507C1 (no) |
| SE (1) | SE9101090D0 (no) |
| SG (1) | SG43180A1 (no) |
| SK (1) | SK280310B6 (no) |
| WO (1) | WO1992018110A1 (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5983956A (en) * | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
| EP0812195B1 (en) | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| GB9526392D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| EP2036544B1 (en) * | 1997-03-20 | 2016-12-28 | Merck Sharp & Dohme Corp. | Dosage form of powder agglomerates |
| US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
| IL133420A (en) * | 1997-08-26 | 2004-07-25 | Aventis Pharma Inc | Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| ATE239447T1 (de) * | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | In verneblern verwendbare, stabilisierte zubereitungen |
| FI105074B (fi) * | 1997-12-31 | 2000-06-15 | Leiras Oy | Farmaseuttisen formulaation valmistusmenetelmä |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| AR022695A1 (es) * | 1999-01-28 | 2002-09-04 | Schering Corp | PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION |
| US6623760B1 (en) | 1999-01-28 | 2003-09-23 | Schering Corporation | Method of preparing particles for agglomeration |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| US20040028746A1 (en) * | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| GB0228826D0 (en) * | 2002-12-11 | 2003-01-15 | Okpala Joseph | Hair technology in creating particles with improved delivery capabilities |
| CA2519779A1 (en) * | 2003-03-26 | 2004-10-14 | Teva Pharmaceutical Industries Ltd. | A process for preparing a pharmaceutical active ingredient with high specific surface area |
| PL1820494T3 (pl) * | 2003-06-13 | 2010-07-30 | Skendi Finance Ltd | Mikrocząstki składające się z estradiolu i cholesterolu |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1675720B1 (en) * | 2003-10-17 | 2011-11-23 | E.I. Du Pont De Nemours And Company | Adhesion of foil to thermoplastic polymers |
| JP2007520546A (ja) * | 2004-02-03 | 2007-07-26 | ケマジス リミティド | モンテルカストナトリウムの安定な非晶質性形態 |
| DE102004048390A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff |
| DE102004048389A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| ES2396471T3 (es) * | 2007-12-13 | 2013-02-21 | Novartis Ag | Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| WO2011110852A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide |
| CA2839398A1 (en) | 2011-06-29 | 2013-01-03 | Bayer Intellectual Property Gmbh | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
| SG11201507286QA (en) * | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
| WO2021219230A1 (en) | 2020-04-30 | 2021-11-04 | Paolo Fiorina | Antiviral treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3978192A (en) * | 1971-09-23 | 1976-08-31 | Sussman Martin V | Method of drawing fibers using a microterraced drawing surface |
| US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
| KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
| US4476130A (en) * | 1982-09-09 | 1984-10-09 | Riker Laboratories, Inc. | 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity |
| JPH08186B2 (ja) * | 1985-06-21 | 1996-01-10 | ゲルゲリイ、ゲルハルト | プロセス材料から反応生成物を製造する方法及びその装置 |
| IT1204826B (it) * | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| KR100229754B1 (ko) * | 1989-11-24 | 1999-11-15 | 샬러 한스, 하우스 한스 루돌프 | 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
-
1991
- 1991-04-11 SE SE9101090A patent/SE9101090D0/xx unknown
-
1992
- 1992-03-24 AU AU15347/92A patent/AU662519B2/en not_active Expired
- 1992-03-24 SG SG1996004975A patent/SG43180A1/en unknown
- 1992-03-24 EP EP95111178A patent/EP0680752B1/en not_active Expired - Lifetime
- 1992-03-24 DE DE69232207T patent/DE69232207T2/de not_active Expired - Lifetime
- 1992-03-24 DK DK95111178T patent/DK0680752T3/da active
- 1992-03-24 SK SK1088-93A patent/SK280310B6/sk not_active IP Right Cessation
- 1992-03-24 KR KR1019930703065A patent/KR100216384B1/ko not_active IP Right Cessation
- 1992-03-24 HU HU9302870A patent/HU211116B/hu unknown
- 1992-03-24 EP EP92907877A patent/EP0580648B1/en not_active Expired - Lifetime
- 1992-03-24 PL PL92301008A patent/PL168232B1/pl unknown
- 1992-03-24 JP JP50719592A patent/JP3400999B2/ja not_active Expired - Lifetime
- 1992-03-24 ES ES92907877T patent/ES2086733T3/es not_active Expired - Lifetime
- 1992-03-24 RO RO93-01336A patent/RO115779B1/ro unknown
- 1992-03-24 DE DE69210601T patent/DE69210601T2/de not_active Expired - Lifetime
- 1992-03-24 DK DK92907877.2T patent/DK0580648T3/da active
- 1992-03-24 AT AT95111178T patent/ATE208613T1/de active
- 1992-03-24 CZ CZ19932116A patent/CZ286936B6/cs not_active IP Right Cessation
- 1992-03-24 ES ES95111178T patent/ES2168322T3/es not_active Expired - Lifetime
- 1992-03-24 WO PCT/SE1992/000186 patent/WO1992018110A1/en active IP Right Grant
- 1992-03-24 RU RU93058260A patent/RU2112507C1/ru active
- 1992-03-24 CA CA002106975A patent/CA2106975C/en not_active Expired - Lifetime
- 1992-03-24 PT PT95111178T patent/PT680752E/pt unknown
- 1992-03-24 EP EP92850062A patent/EP0508969A1/en active Pending
- 1992-03-24 AT AT92907877T patent/ATE137671T1/de active
- 1992-04-10 IE IE114492A patent/IE921144A1/en not_active IP Right Cessation
- 1992-04-10 IS IS3834A patent/IS3834A/is unknown
-
1993
- 1993-10-06 NO NO19933575A patent/NO311867B1/no not_active IP Right Cessation
- 1993-10-08 BG BG98147A patent/BG61474B1/bg unknown
- 1993-10-08 FI FI934429A patent/FI105388B/fi not_active IP Right Cessation
-
1994
- 1994-11-17 EE EE9400417A patent/EE02970B1/xx unknown
-
1995
- 1995-06-07 US US08/479,494 patent/US5562923A/en not_active Expired - Lifetime
-
1996
- 1996-07-23 GR GR960401961T patent/GR3020602T3/el unknown
-
1997
- 1997-04-24 HK HK52497A patent/HK52497A/xx not_active IP Right Cessation
-
2002
- 2002-11-29 JP JP2002347368A patent/JP2003155228A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG61474B1 (en) | Method for conditioning of water soluble substances | |
| SK108793A3 (en) | Method of sewing together of two borders of knitted hose product after its finishing and device for realization of this method | |
| AU681186B2 (en) | Process for conditioning substances | |
| US5874063A (en) | Pharmaceutical formulation | |
| Müller et al. | Applicability of the one-step DVS method for the determination of amorphous amounts for further different hydrophilic and hydrophobic drugs | |
| WO2022083476A1 (zh) | Gefapixant柠檬酸盐的晶型及其制备方法和用途 | |
| WO2003094892A1 (en) | Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations | |
| KR20230117419A (ko) | 화합물의 결정형 및 이의 제조 방법과 적용 |